LBA1 Residual cancer burden (RCB) following neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk HER2+ early-stage breast cancer (eBC)

ESMO Open 2026 Open access

Read full text
Authors: Lajos Pusztai, N. Harbeck, J-F. Boileau, S. Modi, Jianmin Wu, S. Ohno, J. Asselah, S. Escrivá-de-Romaní, A. Yoshida, S-B. Kim, R Li, Z Z Liu
+7 more B. Zurawski, L-M. Tseng, Giuseppe Curigliano, C.M. Kelly, C. Zhang, S. Safdar, F. Symmans
DOI: 10.1016/j.esmoop.2026.107238
Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Cancer Treatment and Pharmacology

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
107238–107238
Publication date
1 May 2026
Language
EN